Dewpoint Therapeutics Raises $77M for Drugs Targeting Biomolecular Condensates

Dewpoint Therapeutics has raised $77 million in a Series B financing round led by ARCH Venture Partners, with participation from both new and existing investors. “We are delighted to have ARCH Venture Partners lead this financing, and to welcome new investors into the condensate field,” said Amir Nashat, managing partner of Polaris Partners and interim CEO of Dewpoint. “Our proprietary platform has already generated two significant external collaborations with Merck and Bayer, and today’s announcement underscores the interest in biomolecular condensates among investors with a track record of backing groundbreaking science.”

Dewpoint’s proprietary platform uses high-throughput methods to test libraries of potential drugs for the desired effect, identifying compounds that modulate biomolecular condensates in specific diseases of immediate interest to Dewpoint and its partners. Approaches to modulating condensates that may positively impact disease include dissolving or forming condensates, modulating the composition of condensates, stabilizing condensates, and selective drug delivery into condensates.

“Dewpoint is the international center of gravity for developing and translating condensate science into drugs,” said Kristina Burow, managing director at ARCH Venture Partners. “The company is well-positioned to leverage novel insights into fundamental biology and utilize this groundbreaking biology to create transformational therapeutics.”

In July 2020, Dewpoint announced an exclusive collaboration with Merck to leverage Dewpoint’s proprietary biomolecular condensate platform for the development of a novel mechanism for the treatment of HIV. In November 2019, Dewpoint announced a collaboration with Bayer for cardiovascular and gynecological diseases.

Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases. In addition to disease areas where Dewpoint has announced collaborations, the company is exploring potential therapeutic opportunities in oncology, neurodegeneration, metabolic disease, and immunology. (Source: Dewpoint Therapeutics Website, 29 September, 2020)